Wall Street analyst estimates for Genenta Science S.p.A. (GNTA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter.
Valuation Ratios
| Price / Book | 0.64 |
| EV / EBITDA | -3.14 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | $1768 | $5096 | $5996 | $41705 | $46508 | $26973 |
| Gross Profit | 0 | -$1768 | -$5096 | -$5996 | -$41705 | -$46508 | -$26973 |
| Research & Development | $3.7M | $4.4M | $3.5M | $5.2M | $6.4M | $5.0M | $2.6M |
| Selling, General & Admin | $908432 | $837353 | $2.4M | $5.6M | $5.1M | $5.1M | $3.7M |
| Operating Expenses | $4.6M | $5.2M | $5.9M | $10.8M | $11.5M | $10.2M | $6.3M |
| Operating Income | -$4.6M | -$5.2M | -$5.9M | -$10.8M | -$11.5M | -$10.2M | -$6.3M |
| EBITDA | -$4.6M | -$5.2M | -$5.8M | -$8.3M | -$11.4M | -$9.3M | -$5.9M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | $384212 |
| Pre-tax Income | -$4.5M | -$5.2M | -$5.8M | -$8.3M | -$11.4M | -$9.3M | -$6.3M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$4.5M | -$5.2M | -$5.8M | -$8.3M | -$11.4M | -$9.3M | -$6.3M |
| EPS | $-0.25 | $-0.31 | $-0.31 | $-0.47 | $-0.64 | $-0.49 | $-0.33 |
| EPS (Diluted) | $-0.25 | $-0.31 | $-0.31 | $-0.47 | $-0.64 | $-0.49 | $-0.33 |
| Shares Outstanding (Diluted) | $18.1M | $18.1M | $18.2M | $18.2M | $18.2M | $18.3M | $19.7M |
Price
| Price | $0.74 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | IT |
Related companies: BRNS · CVM · INMB · IPSC · JUNS · MDCX · MRSN
Explore sector: Healthcare · Biotechnology
More sections of GNTA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks